Arrowhead Files For Regulatory Clearance To Initiate Phase 1/2a Study Of ARO-MMP7 For Idiopathic Pulmonary Fibrosis
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi)
